RRSO and hysterectomy. During 8 (5%) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complications occurred in 3 patients (2%). Four patients (2%) were found to have occult serous tubal intraepithelial carcinoma (STIC) and nine patients (5%) occult cancer. Conclusion RRSO is a safe and feasible procedure in BRCA 1–2 mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.

Conclusion In this small series of aGCT, monitoring FOXL2-mut ctDNA seems relevant to predict RECIST or clinical progression in relapse setting. All cancer deaths were in the FOXL2-mut ctDNA group. Future studies are warranted to confirm if this biomarker can avoid repetitive CTscan for surveillance.

Abstract 2022-RA-823-ESGO Figure 1

Introduction/Background Adult granulosa cell tumors (aGCT) are rare ovarian malignant tumors harboring specific FOXL2 402C>G (C134W) mutation (96%) with multiples relapses. Serum markers are inaccurate in reflecting tumor burden, supporting the identification of new biomarkers.

Methodology Plasma samples were obtained at baseline and every 2–4 weeks for 6 months after C1D1 from patients enrolled in the ALIENOR trial (NCT01770301; 60 patients with relapsed sex cord-stromal tumors treated with chemotherapy +/- bevacizumab (Ray-Coquard, JAMA Oncol 2021)). Digital droplet PCR on circulating cell-free DNA was performed in 137 samples from 23 patients with FOXL2-mutated aGCT to investigate the clinical value of FOXL2 mutation on circulating tumor DNA (FOXL2mut ctDNA) for monitoring disease.

Results FOXL2mut ctDNA was detected in 10 of 23 aGCT patients’ plasma (43%). The sum of the largest diameter of target lesions was 52 mm for FOXL2mut ctDNA negative and 138 mm for positive samples. No clinical factors such as age, number of relapse, metastatic sites, chemotherapy lines or surgery were correlated to FOXL2mut ctDNA levels. Looking at individual monitoring data, a trend between clinical progression and increased FOXL2mut ctDNA levels under therapy was noted. Among 19 patients with samples at baseline and for whom subsequent blood samples were also available at progression or end of study, sensibility, specificity, positive and negative predictive values of FOXL2mut ctDNA were 70%, 89%, 87% and 72% respectively. Only one of 4 patients without FOXL2mut ctDNA at baseline turned positive at progression. With a median follow-up of 42.6 months IC95%[36.8;48.8], 4 patients died (all in the FOXL2mut ctDNA group) (figure 1).

Introduction/Background Recent studies have shown that the research of tumor cells alone cannot explain many phenomena in tumors, so the concept of tumor microenvironment has attracted more and more attention in tumor research. Studies have found that tumor cells need to interact with other cells, especially cancer associated fibroblasts (CAFs) to promote tumor progression. COL5A2 belongs to collagen family and is an important part of extracellular matrix in tumor microenvironment. Therefore, taking COL5A2 as the core to clarify the specific mechanism of the interaction between ovarian cancer cells and CAFs in the ovarian tumor microenvironment can provide a theoretical basis for the development of new treatment strategies for ovarian cancer.

Methodology We analyzed the expression of COL5A2 in 65 cases of ovarian cancer tissue specimens and explored the mechanism of altered COL5A2 expression in ovarian tumor microenvironment. Then we explored the underlying mechanisms of the effect of COL5A2 on cell proliferation, migration and invasion of ovarian cancer in vitro and in vivo.

Results (1) Compared with normal ovarian tissues, COL5A2 is highly expressed in ovarian cancer tissues, and when COL5A2 is highly expressed, the prognosis of ovarian cancer is worse. (2) COL5A2 mainly comes from CAFs. (3) The exosomes carrying ITGB1 secreted by ovarian cancer cells can activate the function of CAFs and promote the expression
and secretion of COL5A2. COL5A2 can activate FAK/P13K/AKT signaling pathway of ovarian cancer cells by combining with ITGAV on the surface of ovarian cancer cells, thus promoting the proliferation, migration and invasion of ovarian cancer.

Abstract 2022-RA-830-ESGO Figure 1

Conclusion: Ovarian cancer cells activate CAFs and promote their expression and secretion of COL5A2 by secreting exosomes carrying ITGB1. COL5A2, which is widely expressed and secreted, can act as the signal molecule feedback on ovarian cancer cells to promote the proliferation, migration and invasion of ovarian cancer.

2022-RA-835-ESGO

AGO-OVARI 2.34/MIROVA: A RANDOMIZED PHASE II TRIAL OF MIRVETUXIMAB SORAVTANSINE (IMGN853) IN FOLATE RECEPTOR ALPHA (FRα) HIGH RECURRENT OVARIAN CANCER ELIGIBLE FOR PLATINUM-BASED CHEMOTHERAPY

1Fabian Trillisch, 2Fabiene Schochter, 3Joung-Won Park-Simon, 4Alexander Reuß, 5Tanja Fehm, 6Pauline Wimbenger, 7Holger Bronger, 8Barbara Schmalfeldt, 9Jalid Sehouli, 10Tanja Fehm, 11Philipp Harter, 12Tanja Fehm, 13Michael Method, 11Philipp Harter, 1 University Hospital LMU Munich, Munich, Germany; 2University Hospital Ulm, Ulm, Germany; 3Hannover Medical School, Hannover, Germany; 4Coordinating Centre for Clinical Trials, Marburg, Germany; 5University Hospital Düsseldorf, Düsseldorf, Germany; 6Technische Universität Dresden, Dresden, Germany; 7University Hospital rechts der Isar, Technical University Munich, Munich, Germany; 8University Hospital Hamburg Eppendorf, Hamburg, Germany; 9Charité – Medical University of Berlin, Berlin, Germany; 10University Hospital Mannheim, Mannheim, Germany; 11Evangelische Kliniken Essen-Mitte, Essen, Germany; 12AGO, Wiesbaden, Germany; 13ImmunoGen Inc, Waltham, MA

Introduction/Background: Following implementation of targeted therapies to first-line treatment, repeated use of bevacizumab and/or PARPi is often not approved nor has been conclusively proven efficacious for all patients with recurrent ovarian cancer. Accordingly, new combination partners for platinum-based chemotherapy become crucial to improve outcome. For the antibody-drug conjugate, Mirvetuximab soravtansine (MIRV), containing a folate receptor alpha (FRα)-binding antibody, patients with high FRα expression, according to PS2+ Scoring (cut-off: ≥75% of tumor cells with FRα membrane staining and ≥2+ intensity) had significant progression-free survival (PFS) improvements (hazard ratio: 0.55) compared to mono-chemotherapy (median PFS 5.6 vs 3.2 months, P = 0.015) in the phase III FORWARD I trial. Preliminary data for combination of MIRV with carboplatin from the phase IIb FORWARD II trial, an ORR of 71% in 17 patients with a median PFS of 15 months, and ORR of 80% in the FRα medium/high (>50% PS2+) subset of 10 patients was noted. MIRV is well-tolerated with a manageable safety profile.

Methodology: Eligible patients for this multicenter, randomized, two-arm, open-label, comparative phase II trial have recurrent, FRα high epithelial cancer of the ovary, fallopian tube or peritoneum and measurable disease. Patients are eligible for platinum-based chemotherapy, had at least one prior chemotherapy, but are not candidates to receive bevacizumab. Patients with wildtype BRCA1/2 mutation status and patients with a deleterious mutation and prior PARPi therapy can be included. Following pre-screening for high FRα expression, 136 patients are randomized (1:1) to a) experimental arm: Carboplatin + MIRV 6 mg/kg IV d1 (6 cycles q21d) followed by MIRV monotherapy until disease progression or b) control arm: Platinum-based chemotherapy (6 cycles) followed by PARPi or standard of care. The primary endpoint PFS will be assessed by modified RECIST 1.1. Key secondary endpoints include overall survival, ORR, and quality of life.

Results: Enrollment started. Conclusion: Trial in Progress.

2022-VA-836-ESGO

ROBOT ASSISTED LAPAROSCOPIC STAGING SURGERY IN EARLY STAGE OF OVARIAN CANCER

1Jung-Hwan Ahn, 2Min Jong Song. 1Obstetrics and Gynecology, Wonju Severance Christian Hospital, Wonju College of Medicine, The Yonsei University of Korea, Gangwon-do, Korea, Repub. of; 2Obstetrics and Gynecology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of

Introduction/Background: Minimal invasive staging surgery is considered as a new standard surgical modality in early stage ovarian cancer. Especially, Robot-assisted surgery is an advanced form to overcome the limitations of conventional laparoscopic surgery, providing steady three-dimensional vision and articulated instruments without tremor and a shorter learning curve. This video aims to demonstrate the robot assisted laparoscopic staging surgery in early stage of ovarian cancer.

Methodology: A 54 years old woman presented with an ovarian cyst suspected to fibroma or granulosa cell tumor on CT scan and elevated CA 125 level. And she was diagnosed with ovarian malignancy, serous carcinoma, after diagnostic laparoscopy and PET-CT scan. But on CT scan, the ovarian lesion was found to be consistent with ovarian cyst. The patient was discharged after 375 minutes and the patient was discharged in five days after surgery without postoperative complications.

Results: Enrolment started. Conclusion: Trial in Progress.